Trials / Active Not Recruiting
Active Not RecruitingNCT06398743
First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 416 (actual)
- Sponsor
- Exact Sciences Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRD | ctDNA MRD test |
Timeline
- Start date
- 2023-06-20
- Primary completion
- 2027-09-01
- Completion
- 2027-12-01
- First posted
- 2024-05-03
- Last updated
- 2025-07-24
Locations
22 sites across 5 countries: Israel, Italy, Japan, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT06398743. Inclusion in this directory is not an endorsement.